Cargando…

A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa

The rapid dissemination of antibiotic resistance combined with the decline in the discovery of novel antibiotics represents a major challenge for infectious disease control that can only be mitigated by investments in novel treatment strategies. Alternative antimicrobials, including silver, have reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Donkor, Gracious Yoofi, Anderson, Greg M., Stadler, Michael, Tawiah, Patrick Ofori, Orellano, Carl D., Edwards, Kevin A., Dahl, Jan-Ulrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597350/
https://www.ncbi.nlm.nih.gov/pubmed/37646510
http://dx.doi.org/10.1128/msphere.00190-23
_version_ 1785125319429062656
author Donkor, Gracious Yoofi
Anderson, Greg M.
Stadler, Michael
Tawiah, Patrick Ofori
Orellano, Carl D.
Edwards, Kevin A.
Dahl, Jan-Ulrik
author_facet Donkor, Gracious Yoofi
Anderson, Greg M.
Stadler, Michael
Tawiah, Patrick Ofori
Orellano, Carl D.
Edwards, Kevin A.
Dahl, Jan-Ulrik
author_sort Donkor, Gracious Yoofi
collection PubMed
description The rapid dissemination of antibiotic resistance combined with the decline in the discovery of novel antibiotics represents a major challenge for infectious disease control that can only be mitigated by investments in novel treatment strategies. Alternative antimicrobials, including silver, have regained interest due to their diverse mechanisms of inhibiting microbial growth. One such example is AGXX, a broad-spectrum antimicrobial that produces highly cytotoxic reactive oxygen species (ROS) to inflict extensive macromolecular damage. Due to the connections identified between ROS production and antibiotic lethality, we hypothesized that AGXX could potentially increase the activity of conventional antibiotics. Using the gram-negative pathogen Pseudomonas aeruginosa, we screened possible synergistic effects of AGXX on several antibiotic classes. We found that the combination of AGXX and aminoglycosides tested at sublethal concentrations led to a rapid exponential decrease in bacterial survival and restored the sensitivity of a kanamycin-resistant strain. ROS production contributes significantly to the bactericidal effects of AGXX/aminoglycoside treatments, which is dependent on oxygen availability and can be reduced by the addition of ROS scavengers. Additionally, P. aeruginosa strains deficient in ROS detoxifying/repair genes were more susceptible to AGXX/aminoglycoside treatment. We further demonstrate that this synergistic interaction was associated with a significant increase in outer and inner membrane permeability, resulting in increased antibiotic influx. Our study also revealed that AGXX/aminoglycoside-mediated killing requires an active proton motive force across the bacterial membrane. Overall, our findings provide an understanding of cellular targets that could be inhibited to increase the activity of conventional antimicrobials. IMPORTANCE: The emergence of drug-resistant bacteria coupled with the decline in antibiotic development highlights the need for novel alternatives. Thus, new strategies aimed at repurposing conventional antibiotics have gained significant interest. The necessity of these interventions is evident especially in gram-negative pathogens as they are particularly difficult to treat due to their outer membrane. This study highlights the effectiveness of the antimicrobial AGXX in potentiating aminoglycoside activities against P. aeruginosa. The combination of AGXX and aminoglycosides not only reduces bacterial survival rapidly but also significantly re-sensitizes aminoglycoside-resistant P. aeruginosa strains. In combination with gentamicin, AGXX induces increased endogenous oxidative stress, membrane damage, and iron-sulfur cluster disruption. These findings emphasize AGXX’s potential as a route of antibiotic adjuvant development and shed light on potential targets to enhance aminoglycoside activity.
format Online
Article
Text
id pubmed-10597350
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-105973502023-10-25 A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa Donkor, Gracious Yoofi Anderson, Greg M. Stadler, Michael Tawiah, Patrick Ofori Orellano, Carl D. Edwards, Kevin A. Dahl, Jan-Ulrik mSphere Research Article The rapid dissemination of antibiotic resistance combined with the decline in the discovery of novel antibiotics represents a major challenge for infectious disease control that can only be mitigated by investments in novel treatment strategies. Alternative antimicrobials, including silver, have regained interest due to their diverse mechanisms of inhibiting microbial growth. One such example is AGXX, a broad-spectrum antimicrobial that produces highly cytotoxic reactive oxygen species (ROS) to inflict extensive macromolecular damage. Due to the connections identified between ROS production and antibiotic lethality, we hypothesized that AGXX could potentially increase the activity of conventional antibiotics. Using the gram-negative pathogen Pseudomonas aeruginosa, we screened possible synergistic effects of AGXX on several antibiotic classes. We found that the combination of AGXX and aminoglycosides tested at sublethal concentrations led to a rapid exponential decrease in bacterial survival and restored the sensitivity of a kanamycin-resistant strain. ROS production contributes significantly to the bactericidal effects of AGXX/aminoglycoside treatments, which is dependent on oxygen availability and can be reduced by the addition of ROS scavengers. Additionally, P. aeruginosa strains deficient in ROS detoxifying/repair genes were more susceptible to AGXX/aminoglycoside treatment. We further demonstrate that this synergistic interaction was associated with a significant increase in outer and inner membrane permeability, resulting in increased antibiotic influx. Our study also revealed that AGXX/aminoglycoside-mediated killing requires an active proton motive force across the bacterial membrane. Overall, our findings provide an understanding of cellular targets that could be inhibited to increase the activity of conventional antimicrobials. IMPORTANCE: The emergence of drug-resistant bacteria coupled with the decline in antibiotic development highlights the need for novel alternatives. Thus, new strategies aimed at repurposing conventional antibiotics have gained significant interest. The necessity of these interventions is evident especially in gram-negative pathogens as they are particularly difficult to treat due to their outer membrane. This study highlights the effectiveness of the antimicrobial AGXX in potentiating aminoglycoside activities against P. aeruginosa. The combination of AGXX and aminoglycosides not only reduces bacterial survival rapidly but also significantly re-sensitizes aminoglycoside-resistant P. aeruginosa strains. In combination with gentamicin, AGXX induces increased endogenous oxidative stress, membrane damage, and iron-sulfur cluster disruption. These findings emphasize AGXX’s potential as a route of antibiotic adjuvant development and shed light on potential targets to enhance aminoglycoside activity. American Society for Microbiology 2023-08-30 /pmc/articles/PMC10597350/ /pubmed/37646510 http://dx.doi.org/10.1128/msphere.00190-23 Text en Copyright © 2023 Donkor et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Donkor, Gracious Yoofi
Anderson, Greg M.
Stadler, Michael
Tawiah, Patrick Ofori
Orellano, Carl D.
Edwards, Kevin A.
Dahl, Jan-Ulrik
A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa
title A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa
title_full A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa
title_fullStr A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa
title_full_unstemmed A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa
title_short A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa
title_sort novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against pseudomonas aeruginosa
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597350/
https://www.ncbi.nlm.nih.gov/pubmed/37646510
http://dx.doi.org/10.1128/msphere.00190-23
work_keys_str_mv AT donkorgraciousyoofi anovelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT andersongregm anovelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT stadlermichael anovelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT tawiahpatrickofori anovelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT orellanocarld anovelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT edwardskevina anovelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT dahljanulrik anovelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT donkorgraciousyoofi novelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT andersongregm novelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT stadlermichael novelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT tawiahpatrickofori novelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT orellanocarld novelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT edwardskevina novelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa
AT dahljanulrik novelrutheniumsilverbasedantimicrobialpotentiatesaminoglycosideactivityagainstpseudomonasaeruginosa